German pharmaceutical company Merck to expand manufacturing in China

A Merck logo seen at the Analytica China international trade show in Shanghai, November 17, 2020./CFP

A Merck logo seen at the Analytica China international trade show in Shanghai, November 17, 2020./CFP

Merck, a Germany-based pharmaceutical company, on Thursday signed an agreement to significantly expand its manufacturing capabilities in Wuxi City, east China’s Jiangsu Province, according to a company statement.

The company will invest nearly 100 million euros ($110 million) over six years in expanding its existing Wuxi production site to increase single-use biopharmaceutical assemblies and custom design capabilities, according to the agreement it signed with Wuxi High-tech Zone in a video conference. .

The investment is expected to create around 1,000 new jobs and be operational by 2024, the company said.

“Over the next five years, we expect strong growth in the bioprocess market, with growth in Asia in the mid-1920s and growth in China exceeding 20% ​​per year on average,” said Marc Jaffre, Managing Director of Merck’s life sciences business in China. “This strategic investment will support biotech innovation in China.”

Wuxi has developed biomedicine as its “flagship industry”, attracting AstraZeneca, General Medicine, Pfizer and more than 1,200 international biomedicine companies. In 2021, the industrial scale of biomedicine in Wuxi reached 140.9 billion yuan ($21 billion), up 20 percent year on year.

Source(s): Xinhua News Agency

Comments are closed.